---
id: 196
title: QuantiFERON-TB Gold vs. TST (Tuberculin Skin Test)
category: diagnostics
subcategory: tuberculosis
tags: [QuantiFERON, IGRA, TST, tuberculin, latent-TB, LTBI]
difficulty: medium
---

## Question

How do QuantiFERON-TB and TST differ? Use **"IGRA: BCG Doesn't Cross-React, 1 Visit, TST: 2 Visits, BCG+ = False+"** framework.

## Answer

### **Tuberculin Skin Test (TST):**

**Procedure:**
- **Intradermal injection** of purified protein derivative (PPD)
- **Read 48-72h** later (measure induration, NOT erythema)

**Interpretation (Induration):**

| Group | Positive | Significance |
|-------|----------|--------------|
| **HIV+, immunosuppressed, close TB contact, CXR fibrotic changes** | **≥5 mm** | High risk |
| **Recent immigrants (<5y), IVDU, residents/employees of high-risk settings, children <4y, healthcare workers** | **≥10 mm** | Moderate risk |
| **Low-risk** (no risk factors) | **≥15 mm** | Generally NOT tested |

**Advantages:**
- **Inexpensive**
- **Widely available**

**Disadvantages:**
- **Requires 2 visits** (place, then read 48-72h later)
- **False positives:** BCG vaccination, non-tuberculous mycobacteria (NTM)
- **False negatives:** Anergy (immunosuppression, severe TB, elderly), recent infection (<8 weeks), improper administration/reading
- **Boosting phenomenon:** Prior TST can boost subsequent response (use 2-step testing for healthcare workers)

### **QuantiFERON-TB Gold (IGRA - Interferon-Gamma Release Assay):**

**Procedure:**
- **Blood test:** Measure interferon-γ release from T cells after stimulation with TB-specific antigens (ESAT-6, CFP-10, TB7.7)

**Interpretation:**
- **Positive:** TB infection (latent or active)
- **Negative:** No TB infection
- **Indeterminate:** Repeat test (immunosuppression, technical error)

**Advantages:**
- **Single visit** (blood draw only)
- **NOT affected by BCG vaccination** (uses TB-specific antigens NOT in BCG)
- **NOT affected by most NTM** (except *M. kansasii*, *M. szulgai*, *M. marinum*)
- **No subjective reading** (lab-based, objective)
- **No boosting phenomenon**

**Disadvantages:**
- **More expensive** than TST
- **Requires lab processing** (within 12-16h of blood draw)
- **Limited availability** in some settings

### **Comparison:**

| Feature | TST | QuantiFERON-TB Gold (IGRA) |
|---------|-----|----------------------------|
| **Visits** | 2 (place, read 48-72h) | 1 (blood draw) |
| **BCG cross-reactivity** | **YES (false positives)** | **NO** |
| **NTM cross-reactivity** | YES | Minimal (except *M. kansasii*, *M. marinum*, *M. szulgai*) |
| **Immunosuppression** | False negatives (anergy) | False negatives (indeterminate result) |
| **Boosting** | YES | NO |
| **Cost** | Low | Higher |
| **Availability** | Widespread | Limited in some settings |

### **Indications for Testing:**

**Test For Latent TB Infection (LTBI) If:**
- **HIV+** (all, regardless of risk)
- **Close contact** of active TB case
- **Immunosuppressed:** TNF-α inhibitors, transplant, chronic steroids, chemotherapy
- **Healthcare workers** (baseline + annual if high-risk setting)
- **Recent immigrants** (<5 years) from high-burden countries
- **Chest X-ray findings** suggestive of prior TB (fibrotic changes, granulomas)
- **IVDU, homeless, incarcerated**

**Do NOT Test Low-Risk Individuals** (no plan to treat LTBI)

### **When to Use TST vs. IGRA:**

**Prefer IGRA If:**
- **BCG-vaccinated** (common in immigrants)
- **Difficulty returning** for TST reading (homeless, unreliable follow-up)
- **Healthcare worker serial testing** (avoid boosting)

**Prefer TST If:**
- **Children <2 years** (IGRA less validated, limited blood volume)
- **Limited resources** (TST cheaper, more available)

**Either Acceptable:** Most situations (both tests equivalent for LTBI diagnosis)

### **Follow-Up After Positive Test:**

**CXR:**
- **Rule out active TB** (all positive TST/IGRA need CXR)

**If CXR Normal:**
- **Latent TB infection (LTBI)** → consider treatment

**If CXR Abnormal:**
- **Sputum AFB smears/cultures, nucleic acid amplification test (NAAT)**
- **Treat as active TB** if confirmed

### **Treatment of LTBI:**

**Preferred Regimens:**
- **Rifampin 600mg PO daily × 4 months** (preferred, better tolerability)
- **Isoniazid + rifapentine** (3HP: weekly × 12 weeks, directly observed)
- **Isoniazid 300mg PO daily × 9 months** (alternative, more hepatotoxicity)

## Key Points

### **IGRA > TST for BCG-Vaccinated:**
- **QuantiFERON NOT affected** by BCG (uses TB-specific antigens)
- **TST false positives** common in BCG-vaccinated immigrants

### **Single Visit (IGRA) vs. Two Visits (TST):**
- **IGRA advantage:** One blood draw
- **TST disadvantage:** Must return 48-72h for reading (compliance issue)

### **Both Detect LTBI, NOT Active TB:**
- **Positive test** = TB infection (latent OR active)
- **CXR + clinical evaluation** required to distinguish

### **Boosting Phenomenon (TST Only):**
- **Repeat TST** can boost response (false "conversion")
- **2-step testing** for healthcare workers (baseline)

### **Clinical Pearls:**
- **BCG-vaccinated:** Use IGRA (NOT TST, false positives)
- **Children <2 years:** TST preferred (IGRA less validated)
- **Positive test → CXR** (rule out active TB)
- **If CXR normal:** Latent TB → treat with rifampin × 4 months (preferred) or INH × 9 months
- **Do NOT test low-risk** individuals (no plan to treat)

## Sources

- [CDC: Latent TB Infection Guidelines 2024]
- [ATS/IDSA: LTBI Testing and Treatment 2024]

## Media

N/A
